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ABSTRACT
Introduction: An increasing number of clinical and
epidemiological studies suggest a possible association
between attention-deficit/hyperactivity disorder (ADHD)
and obesity/overweight. However, overall evidence is
mixed. Given the public health relevance of ADHD and
obesity/overweight, understanding whether and to
what extent they are associated is paramount to plan
intervention and prevention strategies. We describe the
protocol of a systematic review and meta-analysis aimed
at assessing the prevalence of obesity/overweight in
individuals with ADHD versus those without ADHD.
Methods and analysis: We will include studies of
any design (except case reports or case series)
comparing the prevalence of obesity and/or
overweight in children or adults with and without
ADHD (or hyperkinetic disorder). We will search an
extensive number of databases including PubMed,
Ovid databases, Web of Knowledge and Thomson-
Reuters databases, ERIC and CINAHL. No restrictions
of language will be applied. We will also contact
experts in the field for possible unpublished or in
press data. Primary and additional outcomes will be
the prevalence of obesity and overweight, respectively.
We will combine ORs using random-effects models in
STATA V.12.0. The quality of the study will be
assessed primarily using the Newcastle-Ottawa Scale.
Subgroup meta-analyses will be conducted according
to participants’ age (children vs adults) and study
setting (clinical vs general population). We will explore
the feasibility of conducting meta-regression analyses
to assess the moderating effect of age, gender,
socioeconomic status, study setting, geographic
location of the study (low-income, middle-income
countries vs high-income countries), definition of
obesity, method to assess ADHD, psychiatric
comorbidities and medication status.
Ethics and dissemination: No ethical issues are
foreseen. The results will be published in a peer-
reviewed journal and presented at national and
international conferences of psychiatry, psychology,
obesity and paediatrics.
Registration: PROSPERO-National Institute of Health
Research (NIHR) Prospective Register of Systematic
Reviews (CRD42013006410).
INTRODUCTION
Attention-deficit/hyperactivity disorder
(ADHD) is the most common neurodevelop-
mental disorder. According to the recently
published Diagnostic and Statistical Manual
of Mental Disorders, fifth edition, (DSM-5),1
ADHD is characterised by a persistent and
impairing pattern of inattention and/or
hyperactivity/impulsivity. Hyperkinetic dis-
order (HKD), defined in the International
Classification of Diseases, 10th Edition
(ICD-10),2 is a narrower diagnostic category,
requiring symptoms of inattention and
hyperactivity/impulsivity and possibly includ-
ing participants diagnosed with the com-
bined presentation ADHD as per DSM-5.1 A
large body of evidence shows that ADHD is
often comorbid with other psychiatric condi-
tions, such as oppositional defiant disorder
(ODD)/conduct disorder, specific learning
disorders, mood and anxiety disorders and
sleep disturbances.3 4
ADHD is a major public health issue. Its
worldwide-pooled prevalence is estimated at
about 5% in school-age children.5 Impairing
symptoms of ADHD persist in adulthood in
up to 65% of cases,6 with a pooled preva-
lence of adulthood ADHD ∼2.5%.7 Because
Strengths and limitations of this study
▪ Comprehensive search strategy.
▪ Search and data extraction conducted independ-
ently by two authors.
▪ Analytical plan including a series of
meta-regression analyses to address clinically
relevant questions.
▪ No limitations of the systematic review and
meta-analysis are foreseen; limitations of single
included studies will be addressed in the section
‘Assessment of study quality and bias in
included studies’.
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of its core symptoms and comorbid disorders, ADHD
imposes an enormous burden on society in terms of psy-
chological dysfunction, adverse vocational outcomes,
stress on families and societal financial costs. Average
annual incremental costs of ADHD have been recently
estimated at $143–$266 billion in the USA.8 In Europe,
annual national costs range between €1041 and €1529
million.9 A recent study in the UK10 showed that finan-
cial costs were more than four times higher in indivi-
duals when compared with those without ADHD.
While the comorbidity between ADHD and psychiatric
disorders has been extensively studied, the possible asso-
ciation with medical conditions has received less atten-
tion. However, in recent years, it has become clear that
many conditions classically thought to be nervous system
disorders actually do include alterations in other physio-
logical systems.11 As a consequence, an increasing litera-
ture on the association between neuropsychiatric
disorders and medical conditions has emerged in the
past years.
As for ADHD, there has been a rising interest, in par-
ticular, on its possible association with obesity or over-
weight.12 Obesity and overweight, defined in adults as a
body mass index (BMI) ≥30 and ≥25 kg/m2,13 respect-
ively, are a major public health issue. The prevalence of
overweight (including obesity) is currently above 50% in
adults14 and 25% in children15 in several countries. The
USA, where one adult in three presents with obesity,16 is
the most affected country. The UK is the second worst
affected nation: rates of overweight (including obesity)
have tripled in the past three decades, reaching about
60% in adults17 and approximately 33%18 in children.
Obesity and overweight have become a public health
issue also in low-middle income countries such as the
Middle East, North Africa, Latin America and the
Caribbean, where obesity/overweight rates have
approached those found in higher income countries.19
Obesity/overweight is considered as one of the major
causes of morbidity (including risk for cardiovascular
risk, diabetes and cancer) and mortality.16 In addition,
obesity entails an enormous psychological burden
including low self-esteem and social rejection.20 The
worldwide societal costs of obesity are impressive and are
not likely to abate in the future. Indeed, the combined
medical costs related to the treatment of obesity and
associated diseases are estimated to increase in several
countries, for example, by $48–$66 billion/year in the
USA and by £1·9–£2 billion/year in the UK by 2030.16
Clinical21 as well as epidemiological22 23 studies have
shown a significant association between ADHD and
obesity/overweight in children and adults. It has been
suggested that impulsivity and inattention may lead to
irregular and dysregulated eating patterns and lifestyle,
which in turn contribute to weight gain.24 Alternatively,
it has been hypothesised that obesity and ADHD share
common underlying neurobiological abnormalities,
such as dysfunctions in brain reward pathways.24
However, results have not been consistent across studies,
and some failed to find a significant association between
ADHD and obesity/overweight.25 26 It is possible that
factors related to study design (eg, lack of power, cross-
sectional vs longitudinal), selection bias (eg, clinical
samples vs epidemiological ones) or study participants
characteristics (eg, age, gender or medication status)
contribute to explain the inconsistency in currently avail-
able studies. In addition, it is not clear to what extent
ADHD-related and obesity-related factors, such as psychi-
atric comorbidities or socioeconomic status (SES),
account for a possible association between these two
conditions.
Given the public health impact of ADHD and obesity,
systematic empirical evidence on their possible associ-
ation is paramount to design intervention and prevent-
ive programmes addressing these two conditions, when
they co-occur. Currently, although narrative
reviews12 24 27 28 have been published on the relation-
ship between ADHD and obesity/overweight, to our
knowledge, no systematic reviews with study quality
appraisal or meta-analyses are available.
OBJECTIVES
Here, we specifically focus on the prevalence of obesity/
overweight in children and adults with ADHD. We will
conduct a systematic review and meta-analysis of pub-
lished and unpublished studies to address the main
study question: “Is the prevalence of obesity significantly
higher in individuals with compared to those without
ADHD?” We will also conduct meta-regression analyses
to address the impact of possible confounding factors.
Since the variable ‘overweight’ is generally less reported
than ‘obesity’ across studies, we will explore the feasibil-
ity of conducting a separate meta-analysis on the preva-
lence of overweight (rather than obesity) in individuals
with ADHD, as well as to evaluate the role of confound-
ing factors on the relationship of ADHD to overweight.
METHODS
Methods for this systematic review/meta-analysis have
been developed according to recommendations from
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses29 and the Meta-Analysis of
Observational Studies in Epidemiology30 statements.
Selection criteria
Study type
All original, peer-reviewed studies with a control group,
independently from the design (excluding case series
and case studies), will be considered. We will exclude
studies without control group since, given the high het-
erogeneity in the prevalence of obesity according to
country/geographical region, pooling the point preva-
lence rates of obesity without a comparison with a
control group would be poorly informative and its clin-
ical as well as public health implications would not be
clear. Authors of published meeting abstracts reporting
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potentially useful information will be contacted to
obtain full usable data. Experts in the field will be asked
to provide possible further data from studies not yet
published or in press but not yet published online.
Population
ADHD: The population of interest will include children
and/or adults with either: (1) a categorical diagnosis of
ADHD according to the DSM (III, III-R, IV, IV-TR or 5)
or HKD as per the ICD-10 or previous ICD versions; or
(2) a definition of ADHD using a symptoms threshold
on a validated ADHD rating scales; or (3) for adults, a
positive answer to the question: “Did your doctor ever
tell you that you have ADHD?”) or (4) a diagnosis of
ADHD recorded in medical files/registries. We will
explore the feasibility of conducting subgroup analyses
including only studies with a diagnosis of ADHD (or
HKD) confirmed by structured/semistructured inter-
views. We will also evaluate the feasibility of conducting a
meta-regression analysis to assess whether and to what
extent different methods to diagnose ADHD influence
the meta-analysis results. We will also assess whether the
prevalence of obesity in individuals with ADHD differs
between studies reporting a diagnosis of lifetime ADHD
versus those using current diagnosis of ADHD.
We will exclude studies assessing only symptoms of
ADHD, without a diagnosis. We will also exclude studies
including participants with a diagnosis of minimal brain
dysfunction, which would not be comparable with DSM
definitions of ADHD, or with DAMP syndrome (deficit
in attention, motor control and perception), since this
category is controversial31 and, additionally, deficits in
motor control may impact on physical activity levels in
individuals with this syndrome, consequently introdu-
cing possible bias in the estimation of the prevalence of
obesity.
Comparisons: Participants without a diagnosis of
ADHD, from clinical or epidemiological samples.
Age and gender: Studies including individuals of any
age and of both genders will be retained. Subgroup
meta-analyses will be conducted in children and adults,
respectively. We will also conduct a meta-regression ana-
lysis of the moderating effect of age (childhood vs adult-
hood) and we will explore the feasibility of a
meta-regression analysis to evaluate the impact of
gender.
ADHD medication status: Studies will be included
regardless of the past or current treatment of the partici-
pants with psychostimulants (which may be associated
with weight loss, at least during the first month of treat-
ment32). The sensitivity of meta-analytical results to
medication status will be examined in a meta-analysis, if
feasible, limited to psychostimulant-naïve participants.
We will also explore the feasibility of conducting a
meta-regression analysis to explore the moderating
effect of psychostimulant treatment.
Setting: Studies including participants recruited in clin-
ical settings or in the general population will be
included. The sensitivity of meta-analytic results to differ-
ent settings will be examined in two separate
meta-analyses limited to studies conducted in the clinical
setting or in the general population. We will also
conduct a meta-regression analysis to explore the moder-
ating effect of study setting.
Comorbidities: Studies recruiting individuals with ADHD
and psychiatric comorbidities (eg, ODD or mood and
anxiety disorders) will be included. We will explore the
feasibility of meta-regression analyses to assess the mod-
erating effect of psychiatric comorbidities on the preva-
lence of obesity/overweight in individuals with ADHD.
We will exclude studies where, in addition to ADHD, the
presence of a metabolic disorder or any other disorder
impacting on weight (such as diabetes) is an inclusion
criterion.
SES of participants and geographic location of the study:
Studies will not be selected based on the SES of the par-
ticipants or the geographic location where the study was
conducted. We will explore the feasibility of
meta-regression analyses to assess the moderating effect
of SES and geographic location.
Outcome
Primary outcome: The primary outcome will be the point
prevalence of obesity in individuals with ADHD versus
matched comparisons without ADHD. As in a recent
meta-analysis,33 obesity will be defined either (1) on the
basis of self-report (ie, positive answer to the question:
“Do you have obesity?”) or as diagnosis reported in
medical files/registries or (2) as a body mass index
(BMI) (obtained by self-reported or directly measured
height and weight) above a preset value. In adults, the
preset value will be BMI ≥30 kg/m2, as per the defin-
ition adopted by the WHO.34 In children, there is no
consensus on the definition of obesity.35 While some
authors have used BMI >95th or >98th centile for age
and sex (based on national normative data), others have
relied on centile curves that pass through the points of
30 kg/m2, consistent with the definition in adults.36 We
will explore the feasibility of conducting meta-regression
analyses to assess the impact of different obesity defini-
tions in children.
Authors of studies reporting height and weight, or
BMI, but not obesity rates of individuals with and
without ADHD, will be contacted and asked to provide
data on the prevalence of obesity based on the following
definitions: adults: BMI ≥30 kg/m2; children: both BMI
>95th or >98th centile for age and sex (based on
national normative data).
Additional outcome: We will explore the feasibility of
conducting all the analyses replacing obesity with over-
weight, defined either: (1) on the basis of self-report (ie,
positive answer to the question: “Are you overweight?”)
or (2) as a condition reported in medical files/registries;
or (3) as a BMI (obtained by self-reported or measured
height and weight) ≥25 kg/m2 in adults and above 85th
centile in children.
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Search methods for identification of studies
Electronic searches
The strategy for the electronic search has been devel-
oped with the assistance of librarians from the New York
University Medical Library, New York City, New York,
USA.
Electronic searches will be performed in the following
databases:
PubMed
Ovid databases: Ovid MEDLINE
Biological Abstracts
EMBASE Classic+EMBASE
PsycINFO
Web of Knowledge and
Thomas Reuters
databases:
BIOSIS Previews
Inspec
Science Citation Index
Expanded (SCI-Expanded)
Social Sciences Citation Index
(SSCI)
Arts & Humanities Citation
Index (A&HCI)
Conference Proceedings
Citation Index–Science
(CPCI-S)
Conference Proceedings
Citation Index–Social Sciences
and Humanities (CPCI–SSH)
CABI: CAB Abstracts and
Global Health
Food Science and Technology
Abstracts (FSTA)
ERIC
CINAHL
No language or period of publication limitations will
be applied. If needed, a professional translator will be
contacted.
The search terms and syntax for PubMed will be as
follows:
(ADHD OR adhd OR attention deficit disorder with hyper-
activity OR minimal brain disorders OR syndrome hyper-
kinetic OR hyperkinetic syndrome OR hyperactivity
disorder OR hyperactive child syndrome OR childhood
hyperkinetic syndrome OR attention deficit hyperactivity
disorders OR attention deficit hyperactivity disorder OR
adhd attention deficit hyperactivity disorder OR adhd OR
overactive child syndrome OR attention deficit hyperkinetic
disorder OR hyperkinetic disorder OR attention deficit dis-
order hyperactivity OR attention deficit disorders hyper-
activity OR child attention deficit disorder OR hyperkinetic
syndromes OR syndromes hyperkinetic OR hyperkinetic
syndrome childhood) AND (Obes* OR Overweight OR
BMI OR Body Mass Index OR Quetelet’s index OR Body
size OR Adiposity)
Specific search terms and syntax for the other data-
bases are reported in online supplementary appendix 1.
Searching other resources
Manual searches will include scanning of reference lists
of relevant papers retrieved, specialist journals (such as
the Journal of the American Academy of Child and
Adolescent Psychiatry, Journal of Child Psychology and
Psychiatry, European Child and Adolescent Psychiatry, the
American Journal of Psychiatry, International Journal of
Obesity, Obesity and Pediatrics) and conference proceed-
ings (such as the annual meeting of the American
Academy of Child and Adolescent Psychiatry and the
International Congress on Obesity). Authors of abstracts
reporting data on height and weight, but not on
obesity rates in individuals with and without ADHD, will
be contacted and asked to provide, where possible, data
on obesity rates derived by height and weight. We will
also contact members of the European Network for
Hyperkinetic Disorders (Eunethydis), an international
network of researchers in the field of ADHD from
Europe and other continents, and ask them to provide
any unpublished data on the prevalence of obesity in
individuals with ADHD.
IDENTIFICATION AND SELECTION OF STUDIES
Studies identified with electronic and manual searches
will be listed with citation, titles and abstracts in
Endnote (Microsoft, Redmond, Washington, USA);
duplicates will be excluded using the Endnote function
‘remove duplicates’. The eligibility process will be con-
ducted in two separate stages:
1. Two authors (SC and CRMM) will independently
screen title and abstracts of all non-duplicated
papers and will exclude those not pertinent.
A final list will be agreed with discrepancies
resolved by consensus between the two authors.
When consensus is not reached, a third author
(CM-P) will act as arbitrator. If any doubt about
inclusion exists, the article will proceed to the next
stage.
2. The full-text version of the articles passing stage 1
screening will be downloaded and assessed for eli-
gibility by two authors (SC and CRMM), independ-
ently. Discrepancies will be resolved by consensus
between the two authors and, if needed, a third
author (CM-P) will act as arbitrator.
Data from multiple reports of the same study will be
linked together. With regard to prospective studies, we
will consider data at baseline. Where required, we will
contact the corresponding author to inquire on study
eligibility.
DATA EXTRACTION
Two researchers (SC and CRMM) will independently
perform data extraction; any discrepancies will be
resolved by consensus between the two authors. If this is
not possible, another author (CM-P) will make a judge-
ment on the data entered and act as an arbitrator.
4 Cortese S, Moreira Maia CR, Rohde LA, et al. BMJ Open 2014;4:e004541. doi:10.1136/bmjopen-2013-004541
Open Access
 o
n
 7 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2013-004541 on 18 March 2014. Downloaded from 
Data will be extracted and inserted in an Excel sheet.
The following data will be extracted:
1. Publication detail: year and language of publica-
tion, country where the study was conducted;
2. Design: type of study (cross-sectional, case–control,
cohort, etc); study temporality (prospective, retro-
spective); patient enrolment (consecutive, non-
consecutive); setting (clinical vs epidemiological
population study);
3. Study participants details: number, mean age (SD),
gender distribution, SES and ethnicity of partici-
pants with and without ADHD; characteristics of
participants without ADHD (healthy comparisons,
comparisons with psychiatric disorders other than
ADHD, other); psychiatric comorbidities of indivi-
duals with and without ADHD (type and preva-
lence); method to establish the diagnosis of ADHD
(self-reported diagnosis, diagnosis recorded in
medical files/registry, structured or semistructured
interview according to DSM (III, III-R, IV and
IV-TR) or ICD (ICD-10 or previous versions) cri-
teria); medication status of individuals with and
without ADHD (type of medication and percent-
age of treated participants, during and prior to the
study);
4. Outcome measure: method used to define
obesity/overweight (self-reported diagnosis, diag-
nosis in medical file/registry, cut-off in BMI calcu-
lated from self-reported or measured height and
weight); prevalence (unadjusted and, if reported,
adjusted) of obesity and, if reported, of overweight
in individuals with and without ADHD;
5. Covariates included in the adjusted (by the study
authors) ORs effect sizes of obesity prevalence,
such as SES and psychiatric comorbidities.
ASSESSMENT OF STUDY QUALITY AND BIAS
IN INCLUDED STUDIES
The same two authors (SC and CRMM) will independ-
ently perform the assessment of study quality and bias in
included studies. Currently, there is no consensus on
rating methods and appropriateness of quality assess-
ment in meta-analyses of observational studies.37 We will
use primarily the Newcastle-Ottawa Scale38 which has
been recommended by the Cochrane collaboration.39
We will also use the rating system proposed by Paulson
and Bazemore40 and adopted in recent meta-analyses of
observational studies41. This approach rates studies on a
scale of 0–10, assigning two points each for: (1) descrip-
tion of the sampling method; (2) presence of clearly
stated inclusion criteria; (3) assessment of baseline
demographic characteristics; (4) assessment of ethnic
diversity and (5) comprehensive descriptions of out-
comes. Any discrepancies in the rating of study quality
and bias will be resolved by consensus between the two
authors. If this is not possible, another author (CM-P)
will make a judgement on rating and act as an arbitrator.
DATA SYNTHESIS
We will present a narrative synthesis and a quantitative
meta-analysis of the prevalence of obesity/overweight in
participants with and without ADHD.
STATISTICAL ANALYSIS
Calculation of individual study estimates of the prevalence
of obesity/overweight in individuals with ADHD versus
those without ADHD
We will first calculate (or obtain by the study authors)
the prevalence of obesity/overweight in individuals with
and without ADHD from studies that do not report
such prevalence but where data on weight and height
for each participant have been collected. The preva-
lence of obesity and overweight in adults will be calcu-
lated as the percentage of participants with BMI ≥30
and ≥25 kg/m2, respectively. The prevalence of obesity
and overweight in children will be expressed as the per-
centage of participants with age-adjusted and gender-
adjusted BMI z scores (calculated based on national
normative samples) ≥2 and ≥1, respectively, which cor-
respond to 95th and 85th centile, respectively. Given
the lack of consensus in the field on the definition of
paediatric obesity, we will repeat analyses considering
also BMI z score ≥2.5 (which corresponds to the 98th
BMI centile).
The SE and 95% CI of these proportions will then be
determined.
Pooled estimates of the prevalence of obesity/overweight
in individuals with versus those without ADHD
All analyses will be performed using STATAV.12.0.42 The
prevalence of obesity in participants with and without
ADHD from each study will be converted to OR effect
size, with ORs above 1 reflecting increased likelihood of
obesity in individuals with ADHD versus those without
ADHD. Heterogeneity between studies will be tested
with Cochran’s Q test43 and with I2 values. The general
interpretation of I2 values is39:
▸ 0–40%: might not be important
▸ 30–60%: may represent moderate heterogeneity
▸ 50–90%: may represent substantial heterogeneity
▸ 75–100%: considerable heterogeneity.
Meta-analyses of unadjusted and, where available,
adjusted ORs (by the study authors, to control for con-
founding variables) will be carried out using random
effects models, which include sampling and study-level
errors. If available, adjusted risk estimates will be
extracted and analysed. If available, RR and HR will be
extracted and addressed in parallel analyses. We will
assess the presence of publication bias visually by funnel
plot44 and formally by its direct statistical analogue,
Begg’s adjusted rank correlation test,45 using the metabias
program applied in STATA. If publication bias is detected,
we will adjust for this using Duval Tweedie’s method46 in
STATA. We will also assess, if feasible, the moderating role
of gender, age, study setting, geographic location of the
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study, SES, method to assess ADHD, definition of
obesity/overweight, psychiatric comorbidities and medi-
cation status through meta-regression using the metareg
program applied in STATA. The stability of the results
and the influence of studies will be tested using a
leave-one-study-out sensitivity analysis,47 using the metainf
program applied in STATA.
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